(Q42186944)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author

Christian H. Ottensmeier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ellen Kapiteijn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ton Schumacher

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

10

Olivier Michielin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

14

Christian Blank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Sjoerd H van der Burg

8

object named as

Sjoerd van der Burg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Pia Kvistborg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Daisy Philips

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Sander Kelderman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Lois Hageman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Deborah Joseph-Pietras

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Marij J P Welters

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Emanuela Romano

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Carsten Linnemann

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Daniel Speiser

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

John B Haanen

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

1 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

254ra128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25232180%20AND%20SRC:MED&resulttype=core&format=json

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

The interaction properties of costimulatory molecules revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

A direct estimate of the human alphabeta T cell receptor diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

High-throughput identification of antigen-specific TCRs by TCR gene capture

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918

Design and use of conditional MHC class I ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3008918